Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 1

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07559864Phase 2Recruiting

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Role: lead

NCT06838338Phase 1Active Not Recruiting

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Role: lead

NCT06489613Not Yet Recruiting

Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology.

Role: lead

NCT03401372Not ApplicableCompleted

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Role: lead

All 4 trials loaded